MedTrace Logo

A Phase 3 Study to Assess the Efficacy and Safety of PK101 in Patients With Knee Osteoarthritis

NCT04858659 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 354

Last updated 2021-09-22

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy and the safety of PK101 in patients with knee osteoarthritis.

Conditions

Interventions

DRUG

PK101

1 tablet at each time, 2 times a day

DRUG

PK101-002

1 tablet at each time, 2 times a day

DRUG

PK101 placebo

1 tablet at each time, 2 times a day

DRUG

PK101-002 placebo

1 tablet at each time, 2 times a day

Sponsors & Collaborators

  • PMG Pharm Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-20
Primary Completion
2022-03-15
Completion
2022-03-15

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04858659 on ClinicalTrials.gov